FILING ANALYSIS · WEDNESDAY, NOVEMBER 4
BIOCRYST PHARMACEUTICALS INC BCRX — 8-K: Results of Operations and Financial Condition
positive
BioCryst reported strong Q3 financial results with total net revenue of $180.3 million and ORLADEYO net revenue of $174.8 million, and maintained its full-year ORLADEYO revenue guidance while increasing total revenue guidance to $715-730 million.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →